Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction. [PDF]
Rizzo D +3 more
europepmc +1 more source
Bra‐Related Chafing in Female Athletes
JEADV Clinical Practice, EarlyView.
Stéphanie Leclerc‐Mercier +1 more
wiley +1 more source
Commentary: Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis-a critical appraisal of causality and shared pathogenesis. [PDF]
Xu Q.
europepmc +1 more source
Unilateral Hyperkeratotic Lesions With a Sporotrichoid Pattern
JEADV Clinical Practice, EarlyView.
José González Fernández +4 more
wiley +1 more source
Measuring Peripheral Tissue DHA Turnover Using a Novel 13C Enrichment Technique
ABSTRACT Recently, through the use of compound‐specific isotope analysis (CSIA), our lab validated the utility of 13C enrichment (δ13C) of docosahexaenoic acid (DHA) by using a very high δ13C in a diet switch study by measuring brain, liver, and plasma DHA turnover and half‐lives via high‐precision gas chromatography combustion isotope ratio mass ...
Brinley J. Klievik +3 more
wiley +1 more source
Inflammation mediation of the association between brominated flame retardants and psoriasis among U.S. adults. [PDF]
Jiang M +8 more
europepmc +1 more source
Human Cyclophilins—An Emerging Class of Drug Targets
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova +3 more
wiley +1 more source
Severe Hypocalcemia as an Unexpected Trigger for Psoriasis Exacerbation in Chronic Hypoparathyroidism: A Case Report. [PDF]
Hashem W +3 more
europepmc +1 more source
Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben +4 more
wiley +1 more source

